Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Carcinoma, Ovarian Epithelial 2Unspecified Adult Solid Tumor, Protocol Specific 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Ependymoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 40Paclitaxel 30Bevacizumab 16Gemcitabine 14Cyclophosphamide 14liposomal doxorubicin 13Taxes 12Topotecan 11Cisplatin 11Docetaxel 7veliparib 6pembrolizumab 6olaparib 6Doxorubicin 6Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5sargramostim 4fludarabine 4aldesleukin 4Specimen Handling 4Oxaliplatin 4Leucovorin 4Immunoglobulin G 4Filgrastim 4Drug Therapy 4Disulfides 4Biopsy 4talazoparib 3mirvetuximab soravtansine 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Fallopian Tube Neoplasms × Chromatography, Liquid × Clear all
NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Roswell Park Cancer Institute

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡